These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34578109)

  • 1. Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2.
    Hahn F; Häge S; Herrmann A; Wangen C; Kicuntod J; Jungnickl D; Tillmanns J; Müller R; Fraedrich K; Überla K; Kohlhof H; Ensser A; Marschall M
    Pathogens; 2021 Aug; 10(9):. PubMed ID: 34578109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL
    de Vries M; Mohamed AS; Prescott RA; Valero-Jimenez AM; Desvignes L; O'Connor R; Steppan C; Devlin JC; Ivanova E; Herrera A; Schinlever A; Loose P; Ruggles K; Koralov SB; Anderson AS; Binder J; Dittmann M
    J Virol; 2021 Mar; 95(7):. PubMed ID: 33622961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.
    Wang YC; Yang WH; Yang CS; Hou MH; Tsai CL; Chou YZ; Hung MC; Chen Y
    Am J Cancer Res; 2020; 10(8):2535-2545. PubMed ID: 32905393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.
    Bertolin AP; Weissmann F; Zeng J; Posse V; Milligan JC; Canal B; Ulferts R; Wu M; Drury LS; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2425-2443. PubMed ID: 34198323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Single-Cycle Infectious SARS-CoV-2 Virus Replicon Particle System for Use in Biosafety Level 2 Laboratories.
    Malicoat J; Manivasagam S; Zuñiga S; Sola I; McCabe D; Rong L; Perlman S; Enjuanes L; Manicassamy B
    J Virol; 2022 Feb; 96(3):e0183721. PubMed ID: 34851142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
    Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of 3CL
    Rajpoot S; Alagumuthu M; Baig MS
    Curr Res Struct Biol; 2021; 3():9-18. PubMed ID: 33319212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types.
    Hahn F; Wangen C; Häge S; Herrmann L; Herrmann A; Tsogoeva SB; Marschall M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection.
    Vittoria BL; Imbesi C; Irene G; Calì G; Bitto A
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34070359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay.
    Xia Z; Sacco MD; Ma C; Townsend JA; Kitamura N; Hu Y; Ba M; Szeto T; Zhang X; Meng X; Zhang F; Xiang Y; Marty MT; Chen Y; Wang J
    bioRxiv; 2021 Mar; ():. PubMed ID: 33758866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
    Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL
    de Vries M; Mohamed AS; Prescott RA; Valero-Jimenez AM; Desvignes L; O'Connor R; Steppan C; Devlin JC; Ivanova E; Herrera A; Schinlever A; Loose P; Ruggles K; Koralov SB; Anderson AS; Binder J; Dittmann M
    bioRxiv; 2021 Feb; ():. PubMed ID: 32869028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
    Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
    bioRxiv; 2020 Aug; ():. PubMed ID: 32803196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.